Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cell Therapy Plots European Conditional Approval For Heart Regeneration Product

This article was originally published in Scrip

Executive Summary

Cell Therapy Ltd says that following a pre-submission meeting with the European Medicines Agency (EMA) in September, it now plans to begin applying for a conditional marketing authorization (CMA) for Heartcel, its lead allogeneic stem cell therapy, which has been designed to regenerate the heart. Filing is planned for mid-2016, and, if successful, approval could be granted as early as 2017.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register